Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business

Q: How much is Servier paying Edgewise Therapeutics (EWTX) for the muscular dystrophy business?

Servier is paying up to $2.65 billion , including $1.55 billion upfront and up to $1.1 billion in milestones. According to Servier, milestone payments depend on achieving specified regulatory and commercial events, reflecting the development and commercialization progress of sevasemten.

Q: When was the Servier acquisition of Edgewise Therapeutics’ (EWTX) muscular dystrophy business completed?

Servier reported completion of the acquisition on July 13, 2026 , following regulatory clearance and customary closing conditions. According to Servier, the closing transfers the muscular dystrophy business, including sevasemten and related expertise, into Servier’s global rare neurology portfolio.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Servier announced it has completed the acquisition of Edgewise Therapeutics' (Nasdaq: EWTX) muscular dystrophy business for up to $2.65 billion. The consideration includes an upfront payment of $1.55 billion and up to $1.1 billion in potential regulatory and commercial milestone payments, following regulatory clearance and customary closing conditions.

The deal brings Servier the late-stage investigational therapy sevasemten, being studied in a pivotal Becker muscular dystrophy (BMD) cohort and in phase 2 for Duchenne muscular dystrophy (DMD), along with Edgewise’s specialist team. According to Servier, this significantly advances its rare neurology pipeline and supports its Servier 2030 ambition. Sevasemten is an oral fast skeletal myosin inhibitor intended to protect unstable muscle in rare muscular dystrophies, areas with high unmet medical need and, in BMD, no currently approved treatments.

Positive

Transaction value up to $2.65 billion for muscular dystrophy business
$1.55 billion upfront cash payment to Edgewise Therapeutics
Additional potential $1.1 billion in regulatory and commercial milestone payments

Negative

None.

News Explained

The completed sale transfers EWTX’s muscular-dystrophy business to Servier for a $1.55 billion upfront payment, with up to $1.1 billion in milestones.

On July 13, 2026, Servier completed its acquisition of Edgewise Therapeutics' muscular-dystrophy business, transferring the business, sevasemten and the related expert team to Servier while providing consideration to EWTX.

The release states total consideration of up to $2.65 billion, consisting of a $1.55 billion upfront payment and up to $1.1 billion in regulatory and commercial milestone payments.

The transaction therefore has a stated $1.55 billion upfront component, while the remaining $1.1 billion is a ceiling for milestone-based payments rather than a stated closing cash amount.

At March 31, 2026, EWTX reported $33.211 million of cash and equivalents; that pre-closing balance equaled 70.3 days of its first-quarter operating cash use.

Sources and calculations

Cash and equivalents vs quarterly operating cash outflow, in days of cash use $33,211,000 / ($42,543,000 / 90) = [object Object]

News Market Reaction – EWTX

-9.12%

19 alerts

-9.12% Session close to close

-18.6% Trough in 25 hr 8 min

$5.20B Market Cap

0.5x Rel. Volume

In the Jul 13 session, EWTX declined 9.12%, reflecting a notable negative market reaction. Argus tracked a trough of -18.6% from its starting point during tracking. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -9.1% in the session following this news. If shares sold off sharply despite the dea...

Analysis

The stock moved -9.1% in the session following this news. If shares sold off sharply despite the deal’s completion terms matching the earlier $2.65 billion structure, that would contrast with June’s strong reaction and might reflect profit-taking, moderate short positioning, or concern about Edgewise’s post-divestiture pipeline concentration.

Key Figures

Deal value (maximum): $2.65 billion Upfront payment: $1.55 billion Milestone payments: $1.1 billion +1 more

4 metrics

Deal value (maximum) $2.65 billion Total consideration for muscular dystrophy business

Upfront payment $1.55 billion Cash consideration paid at closing

Milestone payments $1.1 billion Potential regulatory and commercial milestones

Median life expectancy 30 years Duchenne muscular dystrophy median life expectancy

Previous Acquisition Reports

1 past event · Latest: Jun 01 (Positive)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 01	Acquisition agreement	Positive	+17.9%	Servier agreed to buy muscular dystrophy business for up to $2.65B.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Acquisition-related announcements have previously coincided with a strong positive move in the shares.

Key Terms

phase 2, pivotal cohort, fast skeletal myosin inhibitor

3 terms

phase 2 medical

"and in phase 2 in Duchenne muscular dystrophy (DMD)."

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

pivotal cohort medical

"currently being investigated in a pivotal cohort in Becker muscular dystrophy (BMD)"

A pivotal cohort is the main group of patients in a clinical trial whose results regulators and companies treat as the decisive test of a treatment’s safety and effectiveness. Investors pay attention because outcomes from this group often determine whether a product can win approval or reach the market, similar to a final exam or spotlight performance that can make or break a company’s prospects.

fast skeletal myosin inhibitor medical

"potential first-in-class fast skeletal myosin inhibitor designed to preserve and protect"

A fast skeletal myosin inhibitor is a drug that targets the specific protein (myosin) responsible for contractions in fast-twitch skeletal muscle fibers, effectively turning down those muscles’ force like a dimmer switch on a light. Investors care because this selective mechanism can treat conditions caused by excessive or uncontrolled muscle contractions without broadly weakening all muscles, which affects clinical trial outcomes, regulatory approval prospects, market size, and commercial risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

07/13/2026 - 08:30 AM

Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies.
The acquired asset and expert team strengthen Servier's commitment to innovate for patients with high unmet medical needs.

SURESNES, France, July 13, 2026 /PRNewswire/ -- Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has completed the acquisition of the muscular dystrophy business of Edgewise Therapeutics Inc. (Nasdaq: EWTX), for up to $2.65 billion, including upfront payment of $1.55 billion as well as up to $1.1 billion in regulatory and commercial milestone payments. This announcement follows regulatory clearance and customary closing conditions.

The acquisition significantly advances Servier's rare neurology pipeline with a late-stage asset, sevasemten, currently being investigated in a pivotal cohort in Becker muscular dystrophy (BMD), and in phase 2 in Duchenne muscular dystrophy (DMD). It also provides Servier with additional capabilities by integrating Edgewise Therapeutics' expertise to advance the development of sevasemten.

Sevasemten is an orally administered potential first-in-class fast skeletal myosin inhibitor designed to preserve and protect unstable muscle against contraction-induced damage in individuals living with rare muscular dystrophy. BMD is a rare, X-linked genetic disorder that causes progressive muscle loss, with currently no approved treatment for patients. The loss of muscle function is irreversible and impacts patients' abilities to perform everyday activities like walking. DMD is a more severe, recessive X-linked genetic, degenerative muscle disorder beginning at birth that causes patients to lose their walking ability by their early teens. It is the most common type of muscular dystrophy with a median life expectancy of around 30 years.

"Delivering precision therapies to people with rare and devastating conditions is at the heart of Servier's mission. The combination of Edgewise's expertise in muscular dystrophy with Servier's global capabilities is a major step forward to accelerate the development of innovative treatments for people living with Becker and Duchenne", said Olivier Laureau, President of Servier. "This acquisition is a strategic milestone in achieving our Servier 2030 ambition in rare neurology."

"Servier's strong commitment to patients, growing focus on rare neurology, and established global capabilities position them as the optimal partner to advance the muscular dystrophy business", said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise Therapeutics.

Contacts
Servier Group, Olympe Muller
olympe.muller@servier.com

PDF - https://mma.prnewswire.com/media/3005524/PDF.pdf
Logo - https://mma.prnewswire.com/media/2766991/Servier_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/servier-completes-the-acquisition-of-edgewise-therapeutics-muscular-dystrophy-business-302822911.html

SOURCE Servier

FAQ

What did Servier acquire from Edgewise Therapeutics (NASDAQ: EWTX) in July 2026?

Servier acquired Edgewise Therapeutics’ muscular dystrophy business, including sevasemten and its expert team. According to Servier, the deal adds a late-stage Becker muscular dystrophy asset and a phase 2 Duchenne program, strengthening its rare neurology pipeline and development capabilities in muscular dystrophies.

How much is Servier paying Edgewise Therapeutics (EWTX) for the muscular dystrophy business?

Servier is paying up to $2.65 billion, including $1.55 billion upfront and up to $1.1 billion in milestones. According to Servier, milestone payments depend on achieving specified regulatory and commercial events, reflecting the development and commercialization progress of sevasemten.

What is sevasemten in the Servier and Edgewise Therapeutics (EWTX) transaction?

Sevasemten is an orally administered, investigational fast skeletal myosin inhibitor targeting rare muscular dystrophies. According to Servier, it is in a pivotal Becker muscular dystrophy cohort and phase 2 Duchenne study, aiming to protect unstable muscle from contraction-induced damage in affected individuals.

How does the Servier and Edgewise Therapeutics (EWTX) deal impact Servier’s rare neurology strategy?

The acquisition significantly expands Servier’s rare neurology pipeline with a late-stage asset and specialist team. According to Servier, integrating Edgewise’s muscular dystrophy expertise supports its Servier 2030 ambition and enhances its ability to develop precision therapies for Becker and Duchenne muscular dystrophies.

What unmet medical needs in BMD and DMD are addressed in the Servier–Edgewise (EWTX) deal?

The deal targets Becker and Duchenne muscular dystrophies, which cause progressive, irreversible muscle loss. According to Servier, BMD currently has no approved treatments, while DMD often leads to loss of walking ability in early teens and a median life expectancy around 30 years.

When was the Servier acquisition of Edgewise Therapeutics’ (EWTX) muscular dystrophy business completed?

Servier reported completion of the acquisition on July 13, 2026, following regulatory clearance and customary closing conditions. According to Servier, the closing transfers the muscular dystrophy business, including sevasemten and related expertise, into Servier’s global rare neurology portfolio.